Abd Elkodous M, Olojede S O, Morsi Mahmoud, El-Sayyad Gharieb S
Department of Electrical and Electronic Information Engineering, Toyohashi University of Technology Toyohashi Aichi 441-8580 Japan
Center for Nanotechnology (CNT), School of Engineering and Applied Sciences, Nile University Sheikh Zayed Giza 16453 Egypt.
RSC Adv. 2021 Aug 2;11(43):26463-26480. doi: 10.1039/d1ra04835j.
Once the World Health Organization (WHO) declared the COVID-19 outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Here we review the most recent data on the novel SARS-CoV-2 pathogen. We analyzed its etiology, pathogenesis, diagnosis, prevention, and current medications. After that, we summarized the promising drug delivery application of nanomaterial-based systems. Their preparation routes, unique advantages over the traditional drug delivery routes and their toxicity though risk analysis were also covered. We also discussed in detail the mechanism of action for one example of drug-loaded nanomaterial drug delivery systems (Avigan-contained nano-emulsions). This review provides insights about employing nanomaterial-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reducing their toxicity, and to increase their efficiency.
一旦世界卫生组织(WHO)宣布新型冠状病毒肺炎(COVID-19)疫情为大流行,全球研究人员便展开了大规模努力来对抗这种新出现的传染病。在此,我们回顾关于新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病原体的最新数据。我们分析了其病因、发病机制、诊断、预防及当前的治疗药物。之后,我们总结了基于纳米材料的系统在药物递送方面的应用前景。还涵盖了它们的制备途径、相较于传统药物递送途径的独特优势以及通过风险分析得出的毒性情况。我们还详细讨论了一种载药纳米材料药物递送系统(含阿比多尔纳米乳剂)的作用机制。本综述为采用基于纳米材料的药物递送系统治疗COVID-19提供了见解,以提高现有药物的生物利用度、降低其毒性并提高其疗效。